Read by QxMD icon Read

Clinical Genitourinary Cancer

Jim Leng, Adil S Akthar, Russell Z Szmulewitz, Peter H O'Donnell, Randy F Sweis, Sean P Pitroda, Norm Smith, Gary D Steinberg, Stanley L Liauw
BACKGROUND: Bladder cancer is commonly diagnosed in patients ineligible for radical cystectomy or chemoradiotherapy (chemo-RT) with cisplatin or fluorouracil with mitomycin. We assessed tolerability, efficacy, and toxicity of hypofractionated radiotherapy with capecitabine in this challenging population. PATIENTS AND METHODS: Patients with high-grade urothelial bladder cancer ineligible for radical cystectomy or high-intensity chemo-RT underwent maximal transurethral resection of bladder tumor followed by capecitabine (median, 825 mg/m2 per day 2 times a day) and radiation (median, 55 Gy in 2...
October 12, 2018: Clinical Genitourinary Cancer
Anas M Saad, Mohamed M Gad, Muneer J Al-Husseini, Inas A Ruhban, Mohamad Bassam Sonbol, Thai H Ho
BACKGROUND: Renal-cell carcinoma (RCC) is one of the common malignancies in the United States. RCC incidence and mortality have been changing for many reasons. We performed a thorough investigation of incidence and mortality trends of RCC in the United States using the cell Surveillance, Epidemiology, and End Results (SEER) database. PATIENTS AND METHODS: The 13 SEER registries were accessed for RCC cases diagnosed between 1992 and 2015. Incidence and mortality were calculated by demographic and tumor characteristics...
October 11, 2018: Clinical Genitourinary Cancer
Cristina Masini, Maria Giuseppa Vitale, Marco Maruzzo, Giuseppe Procopio, Ugo de Giorgi, Sebastiano Buti, Sabrina Rossetti, Roberto Iacovelli, Francesco Atzori, Laura Cosmai, Francesca Vignani, Giuseppe Prati, Sarah Scagliarini, Annalisa Guida, Annalisa Berselli, Carmine Pinto
BACKGROUND: Pazopanib has been approved for first-line treatment of patients with metastatic renal-cell carcinoma on the basis of clinical trials that enrolled only patients with adequate renal function. Few data are available on the safety and efficacy of pazopanib in patients with renal insufficiency. This study investigated the effect of kidney function on treatment outcomes in such patients. PATIENTS AND METHODS: We retrospectively analyzed data of metastatic renal-cell carcinoma patients treated with pazopanib from January 2010 to June 2016 with respect to renal function...
October 10, 2018: Clinical Genitourinary Cancer
Felix Preisser, Elio Mazzone, Sophie Knipper, Sebastiano Nazzani, Marco Bandini, Shahrokh F Shariat, Zhe Tian, Fred Saad, Francesco Montorsi, Kevin C Zorn, Markus Graefen, Derya Tilki, Pierre I Karakiewicz
BACKGROUND: The objective of this study was to investigate positive surgical margin (PSM) rates in patients with prostate cancer treated with radical prostatectomy (RP) and assess PSM impact on cancer-specific mortality (CSM). PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015), we identified men who underwent RP with pathologic T2 or T3a stage. Annual trends of PSM rates were plotted. Subgroups focused on geographic regions, namely the North Central, Northeast, South, and West...
October 4, 2018: Clinical Genitourinary Cancer
Alireza Aminsharifi, Lauren E Howard, Christopher L Amling, William J Aronson, Matthew R Cooperberg, Christopher J Kane, Martha K Terris, Thomas J Polascik, Stephen J Freedland
PURPOSE: To investigate the preoperative use of combination metformin and statin versus monotherapy on biochemical recurrence (BCR) after radical prostatectomy (RP) in diabetic men. PATIENTS AND METHODS: Data of 843 diabetic men who underwent RP were stratified on the basis of preoperative use of no drug or of metformin, statin, or both. Multivariable Cox models were used to test the association between treatment and BCR. In a secondary analysis, models were stratified by race and body mass index (BMI) and further adjusted for glycated hemoglobin (HbA1c)...
October 4, 2018: Clinical Genitourinary Cancer
Cécile Vicier, Lillian Werner, Jonathan Chipman, Lauren C Harshman, Dattatraya H Patil, Raina N Fichorova, Jennifer R Rider, Martin G Sanda, Lorelei A Mucci, Christopher J Sweeney
BACKGROUND: Inflammation and infections have been associated with prostate cancer progression. We assessed whether elevated serum cytokines or T. vaginalis seropositivity at the time of diagnosis was associated with higher grade or lethal prostate cancer. PATIENTS AND METHODS: Men with localized or metastatic prostate cancer were included in this study. Cytokine serum levels including interleukin (IL)-1α, IL-1β, IL-2, IL-6, IL-8, monocyte chemotactic protein 1 (CCL-2), tumor necrosis factor α, and growth-regulated oncogene α (CXCL-1) using a multiplex enzyme-linked immunosorbent assay and T...
October 4, 2018: Clinical Genitourinary Cancer
Shintaro Narita, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Mitsuru Saito, Takamitsu Inoue, Shigeru Satoh, Hiroshi Nanjo, Norihiko Tsuchiya, Koji Mitsuzuka, Takuya Koie, Sadafumi Kawamura, Chikara Ohyama, Tatsuo Tochigi, Yoichi Arai, Tomonori Habuchi
BACKGROUND: To investigate the clinical outcomes in patients with high-risk prostate cancer (PCa) treated with neoadjuvant chemohormonal therapy (NCHT) before radical prostatectomy (RP). PATIENTS AND METHODS: Our NCHT protocol involved complete androgen blockade followed by 6 cycles of docetaxel (30 mg/m2 ) plus estramustine phosphate (560 mg). NCHT was provided to 60 patients with PCa before RP, and we compared the clinical and pathologic outcomes with those of 349 patients with high-risk PCa who underwent RP alone using propensity score matching...
September 27, 2018: Clinical Genitourinary Cancer
Nermarie Velazquez, Benjamin Press, Audrey Renson, James S Wysock, Samir Taneja, William C Huang, Marc A Bjurlin
INTRODUCTION: Penectomy for PC is useful in staging, disease prognosis, and treatment. Limited studies have evaluated its surgical complications. We sought to assess these complications and determine predictive models to create a novel risk score for penectomy complications. PATIENTS AND METHODS: A retrospective review of patients undergoing PC surgical management from the 2005-2016 American College of Surgeons National Surgical Quality Improvement Program was performed...
September 27, 2018: Clinical Genitourinary Cancer
Omar Abdel-Rahman
BACKGROUND: The current study aims to provide an assessment of the impact of diabetes mellitus and its metformin treatment on the outcomes of castration-resistant prostate cancer (CRPC) within a pooled dataset of 3 clinical trials. MATERIALS AND METHODS: This is a pooled analysis of the comparator arms of 3 clinical trials (NCT00988208; NCT00273338; NCT00519285) that evaluated docetaxel/prednisone in chemotherapy-naive patients with CRPC. Overall survival according to patient subsets (nondiabetic patients, diabetic metformin patients, and diabetic non-metformin patients) was assessed using Kaplan-Meier analysis and log-rank testing...
September 27, 2018: Clinical Genitourinary Cancer
Sebastiano Nazzani, Felix Preisser, Elio Mazzone, Michele Marchioni, Marco Bandini, Zhe Tian, Francesco A Mistretta, Shahrokh F Shariat, Denis Soulières, Emanuele Montanari, Pietro Acquati, Alberto Briganti, Luca Carmignani, Pierre I Karakiewicz
BACKGROUND: Few data examined the potential survival benefit of chemotherapy (CHT) in the setting of metastatic upper urinary tract urothelial carcinoma (mUTUC). We hypothesized that a survival benefit might be associated with the use of CHT in nonsurgically treated primary mUTUC and tested this hypothesis within a large population-based cohort. PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2014), we identified 539 patients with nonsurgically treated primary mUTUC...
September 27, 2018: Clinical Genitourinary Cancer
Mina Lee, Haemin Hong, Won Kim, Li Zhang, Terence W Friedlander, Lawrence Fong, Amy M Lin, Eric J Small, Xiao X Wei, Tammy J Rodvelt, Brigid Miralda, Brian Stocksdale, Charles J Ryan, Rahul Aggarwal
BACKGROUND: Patients with biochemically recurrent prostate cancer and short prostate-specific antigen doubling time (PSADT) are at risk for metastasis yet may wish to avoid androgen deprivation therapy. Itraconazole may have antitumor activity without affecting circulating androgen levels. We therefore evaluated itraconazole as a potentially noncastrating treatment approach in biochemically recurrent prostate cancer. PATIENTS AND METHODS: Patients with biochemically recurrent prostate cancer and PSADT ≤ 15 months, with serum testosterone > 150 ng/dL, were prospectively enrolled...
September 24, 2018: Clinical Genitourinary Cancer
Marco Bandini, Sebastiano Nazzani, Michele Marchioni, Felix Preisser, Zhe Tian, Marco Moschini, Firas Abdollah, Nazareno Suardi, Markus Graefen, Francesco Montorsi, Shahrokh F Shariat, Fred Saad, Alberto Briganti, Pierre I Karakiewicz
BACKGROUND: The rate of noninterventional treatment (NIT) in prostate cancer (PCa) active surveillance (AS) candidates is on the rise. However, contemporary data are unavailable. We described community-based NIT rates within 16 Surveillance Epidemiology and End Results (SEER) registries between 2010 and 2014. PATIENTS AND METHODS: We identified 23,360 PCa patients who fulfilled the University of California San Francisco AS criteria (prostate-specific antigen [PSA] < 10 ng/mL, clinical T stage ≤ T2a, Gleason score ≤ 6, and positive cores < 33%)...
September 22, 2018: Clinical Genitourinary Cancer
Mounsif Azizi, Dominic H Tang, Daniel Verduzco, Charles C Peyton, Juan Chipollini, Zhigang Yuan, Braydon J Schaible, Jun-Min Zhou, Peter A Johnstone, Anna Giuliano, Jasreman Dhillon, Philippe E Spiess
PURPOSE: To assess the prognostic value of PI3K-AKT-mTOR signaling pathway up-regulation in a contemporary cohort of penile squamous-cell carcinoma (PSCC) patients. PATIENTS AND METHODS: Tissue microarrays were constructed for 57 patients with invasive PSCC treated at our institution between 2000 and 2013. Immunohistochemical staining was performed for PTEN, AKT, and S6. Human papillomavirus (HPV) in-situ hybridization for high-risk subtypes was also performed. Biomarker expression was evaluated by a semiquantitative H score...
September 22, 2018: Clinical Genitourinary Cancer
Davide Arcaniolo, Celeste Manfredi, Luca Cindolo, Michele Marchioni, Eduardo P Zukovski, Vincenzo Mirone, Uzoma A Anele, Georgi Guruli, Baruch Mayer Grob, Marco De Sio, Riccardo Autorino
The aim of the present study is to systematically review current evidence regarding the association between perioperative blood transfusions (PBT) and oncological outcomes of patients with renal cell carcinoma undergoing nephrectomy procedures. A computerized bibliographic search was conducted to identify pertinent studies. The Population, Intervention, Comparator, Outcome (PICO) study design approach was used to define study eligibility according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) criteria...
September 20, 2018: Clinical Genitourinary Cancer
Anis A Hamid, Sarah C Markt, Cécile Vicier, Kathleen McDermott, Paul Richardson, Vincent T Ho, Christopher J Sweeney
BACKGROUND: High-dose chemotherapy (HDCT) with autologous stem-cell transplantation (aSCT) has been a standard therapy for relapsed metastatic germ-cell tumors (GCTs) over the last 2 decades, but there have been many changes in practice over time with respect to stem-cell source, mobilization, and conditioning regimens. Mobilization is impaired with greater cisplatin exposure. PATIENTS AND METHODS: Patients with relapsed GCT who received HDCT/aSCT at Dana-Farber Cancer Institute between 1997 and 2017 were identified...
September 19, 2018: Clinical Genitourinary Cancer
Young Hyo Choi, Min Yong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Chan Kyo Kim, Byung Kwan Park, Hyun Moo Lee
BACKGROUND: The purpose of the study was to compare cancer detection rates between 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) and multiparametric magnetic resonance imaging (mpMRI)-guided target prostate biopsy (MRI-TBx) according to prostate-specific antigen (PSA) level in biopsy-naive patients. PATIENTS AND METHODS: A retrospective study was conducted in 2009 biopsy-naive patients with suspected prostate cancer (PSA ≤20 ng/mL). Patients underwent TRUS-Bx (n = 1786) or MRI-guided target prostate biopsy (MRI-TBx; n = 223) from September 2013 to March 2017 and were stratified according to each of 4 PSA cutoffs...
September 13, 2018: Clinical Genitourinary Cancer
Andrea Necchi, Gregory R Pond, Marco Moschini, Elizabeth R Plimack, Gunter Niegisch, Evan Y Yu, Aristotelis Bamias, Neeraj Agarwal, Ulka Vaishampayan, Christine Theodore, Srikala S Sridhar, Jonathan E Rosenberg, Joaquim Bellmunt, Andrea Gallina, Renzo Colombo, Francesco Montorsi, Alberto Briganti, Matthew D Galsky
BACKGROUND: Limited information is available about the pattern of relapse after perioperative chemotherapy with radical cystectomy (RC) vs. RC alone in muscle-invasive bladder cancer. PATIENTS AND METHODS: Data from 1082 patients of the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium database, treated from February 1990 to December 2013 at 27 centers in the United States, Europe, Israel, and Canada, were collected. Locoregional relapse was defined as any pelvic lymph node or soft tissue-only recurrences...
September 13, 2018: Clinical Genitourinary Cancer
Nils Kroeger, Haoran Li, Guillermo De Velasco, Frede Donskov, Hao-Wen Sim, Viktoria Stühler, J Connor Wells, Igor Stukalin, Johannes Heide, Jens Bedke, Neeraj Agarwal, Hiral Parekh, Brian I Rini, Jennifer J Knox, Allan Pantuck, Toni K Choueiri, Daniel Yick Chin Heng
BACKGROUND: Smoking increases the risk of developing renal cell carcinoma (RCC) but the effect of tobacco consumption on survival outcome of patients with metastatic RCC (mRCC) treated with targeted therapies has not been well characterized. PATIENTS AND METHODS: The primary outcome was overall survival (OS) and secondary outcome was progression-free survival (PFS). Patients with mRCC were categorized as current, former, and nonsmokers at the time of starting targeted therapy...
September 12, 2018: Clinical Genitourinary Cancer
Pavlos Msaouel, Andrew L Hong, Elizabeth A Mullen, Michael B Atkins, Cheryl Lyn Walker, Chung-Han Lee, Marcus A Carden, Giannicola Genovese, W Marston Linehan, Priya Rao, Maria J Merino, Howard Grodman, Jeffrey S Dome, Conrad V Fernandez, James I Geller, Andrea B Apolo, Najat C Daw, H Courtney Hodges, Marva Moxey-Mims, Darmood Wei, Donald P Bottaro, Michael Staehler, Jose A Karam, W Kimryn Rathmell, Nizar M Tannir
Renal medullary carcinoma (RMC) is one of the most aggressive renal cell carcinomas. It predominantly afflicts young adults and adolescents with sickle cell trait and other sickle hemoglobinopathies, and is refractory to targeted and antiangiogenic therapies used in patients with clear-cell renal cell carcinoma. Platinum-based cytotoxic chemotherapy is the mainstay for RMC treatment. On the basis of recent advances in the diagnosis, management, and clinical trial development for RMC, a panel of experts met in October 2017 and developed updated consensus recommendations to inform clinicians, researchers, and patients...
September 12, 2018: Clinical Genitourinary Cancer
Julie Wang Skøtt, Jakob Lauritsen, Michael Bay Kreiberg, Gedske Daugaard, Mikkel Bandak
BACKGROUND: Compensated Leydig cell (LC) dysfunction, defined by elevated serum levels of luteinizing hormone (LH) in combination with normal total testosterone levels, is common in testicular cancer (TC) survivors. The association between this condition and quality of life is unknown. We aimed to clarify if TC survivors with compensated LC dysfunction have impaired quality of life. PATIENTS AND METHODS: In total, 147 long-term TC survivors were included. On the basis of a single measurement of testosterone and LH, compensated LC dysfunction was defined by age-adjusted levels of LH above normal range combined with testosterone levels within the normal range...
September 8, 2018: Clinical Genitourinary Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"